<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721409</url>
  </required_header>
  <id_info>
    <org_study_id>A5481003</org_study_id>
    <secondary_id>2008-002392-27</secondary_id>
    <nct_id>NCT00721409</nct_id>
  </id_info>
  <brief_title>Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer</brief_title>
  <official_title>Phase 1/2, Open-label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Letrozole Plus Pd 0332991 (Oral Cdk 4/6 Inhibitor) And Letrozole Single Agent For The First-line Treatment Of Er Positive, Her2 Negative Advanced Breast Cancer In Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess
      the effect of the combination on advanced breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2008</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">November 29, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1</measure>
    <time_frame>Maximum treatment duration (approximately 55 months)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events at Phase 1</measure>
    <time_frame>Maximum treatment duration (approximately 55 months)</time_frame>
    <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities at Phase 1</measure>
    <time_frame>Cycle 2 (4 weeks)</time_frame>
    <description>Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets &lt;25,000/μL, ANC &lt;500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count &lt;50,000/μL; ANC &lt;1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment</measure>
    <time_frame>From randomization date to date of first documentation of progression or death (assessed up to 41 months)</time_frame>
    <description>PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1</measure>
    <time_frame>From Baseline up to end of study (assessed up to 55 months)</time_frame>
    <description>Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1</measure>
    <time_frame>From Baseline up to end of study (assessed up to 55 months)</time_frame>
    <description>CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging &gt;= 4 weeks after initial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1</measure>
    <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
    <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1</measure>
    <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
    <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1</measure>
    <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
    <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1</measure>
    <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
    <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1</measure>
    <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
    <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1</measure>
    <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
    <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1</measure>
    <time_frame>Cycle 2 Day 14, Cycle 2 Day 28</time_frame>
    <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1</measure>
    <time_frame>Cycle 2 Day 14, and Cycle 2 Day 28</time_frame>
    <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1</measure>
    <time_frame>Cycle 2 Day 14, and Cycle 2 Day 28</time_frame>
    <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1</measure>
    <time_frame>Cycle 1 Day 1 prior to dosing, Cycle 1 Day 14 (2, 4 [prior to meal], 8, 24, 48, and 96 hours after dosing of Palbociclib), Cycle 2 Day 1 and Day 14 (prior to and 4 hours after dosing of letrozole)</time_frame>
    <description>Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (&lt;) 60 msec(borderline) and greater than or equal to (&gt;=) 60 msec (prolonged) were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at Phase 2</measure>
    <time_frame>From randomization until death (assessed up to 41 months)</time_frame>
    <description>Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment</measure>
    <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
    <description>Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment</measure>
    <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
    <description>Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response at Phase 2 - Investigator Assessment</measure>
    <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
    <description>Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CBR at Phase 2 - Investigator Assessment</measure>
    <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
    <description>CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment</measure>
    <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
    <description>Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2</measure>
    <time_frame>Baseline, End of treatment (approximately 41 months)</time_frame>
    <description>The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (&quot;no pain&quot; or &quot;does not interfere&quot;) to 10 (&quot;pain as bad as you can imagine&quot; or &quot;completely interferes&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2</measure>
    <time_frame>Baseline, End of treatment (approximately 41 months)</time_frame>
    <description>The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (&quot;no pain&quot; or &quot;does not interfere&quot;) to 10 (&quot;pain as bad as you can imagine&quot; or &quot;completely interferes&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1</measure>
    <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
    <description>Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67</measure>
    <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
    <description>Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1</measure>
    <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
    <description>Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression &gt;0 and Negative: any expression=0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2</measure>
    <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
    <description>Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2</measure>
    <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
    <description>One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs (All Causalities) at Phase 2</measure>
    <time_frame>Maximum treatment duration (approximately 41 months)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent adverse events were those with initial onset or that worsen in severity after the first dose of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events at Phase 2</measure>
    <time_frame>Maximum treatment duration (approximately 41 months)</time_frame>
    <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>letrozole + PD 0332991</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>letrozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332991</intervention_name>
    <description>125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>2.5 mg/d tablets orally on a continuous regimen</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>2.5 mg/d tablets orally on a continuous regimen</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inoperable estrogen receptor positive and HER2 negative breast cancer.

          -  Postmenopausal status.

          -  Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2
             - CCND1 amplification and/or loss of p16 as determined by the central laboratory.

          -  Acceptable bone marrow, liver and kidney function.

        Exclusion Criteria:

          -  Prior or concomitant treatment for advanced breast cancer.

          -  Other major cancer in the past 3 years.

          -  Important cardiovascular events in the past 6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hematology Oncology Medical group Inc.</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Alhambra</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA West Medical Pharmacy (Drug Management Only)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA West Medical Pharmacy</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Management Only: UCLA West Medical Pharmacy</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Management Only</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regulatory Managment</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI -US Central Administration (Regulatory Management)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI Central Administration (Regulatory Management)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI Central Administration (Regulatory Managment Only)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRIO-US Central Administration</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA, Hematology/Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westwood Bowyer Clinic, Peter Morton Medical Building</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hematology Oncology Medical Group, Inc</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sansum Santa Barbara Medical Foundation Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology Corporation</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Monica-UCLA Medical Center and Orthopaedic Hospital</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology Oncology-Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Santa Clarita</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialties</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialties</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Resurrection Medical Group</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Oncology-Hematology Associates</name>
      <address>
        <city>Crystal Lake</city>
        <state>Illinois</state>
        <zip>60014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology</name>
      <address>
        <city>Highland Park</city>
        <state>Illinois</state>
        <zip>60035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Oncology-Hematology Associates</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regulatory Office: Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Dallas Presbyterian Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Products Center (IPC) (drug shipment only)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Research and Clinical Pharmacy (Drug Shipment Only)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Research and Clinical Pharmacy</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Gainesville</city>
        <state>Virginia</state>
        <zip>20155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Woodbridge</city>
        <state>Virginia</state>
        <zip>22191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSSS Champlain-Charles-Le Moyne Local HS-0054</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin, CRLCC</name>
      <address>
        <city>ANGERS Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis, Onkologischer Schwerpunkt am Oskar-Helene-Heim</name>
      <address>
        <city>Berlin</city>
        <zip>14195</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Haematologie-Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universitaet Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik und Poliklinik fuer Gynaekologie, Martin-Luther-Universitaet Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum fuer Tumorerkrankungen</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenaerzte Pruener Gang Abts &amp; Partner</name>
      <address>
        <city>Kiel</city>
        <zip>24103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Universitaetsklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum - MOP</name>
      <address>
        <city>Muenchen</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik vom Roten Kreuz</name>
      <address>
        <city>Muenchen</city>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mutterhaus der Borromaeerinnen, Innere Medizin I</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Margit Korhaz, Onkologia</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet, Kemoterapia B</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fovarosi Onkormanyzat Uzsoki Utcai Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz, Onkoradiologia</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Korhaz és Egyetemi Oktato Korhaz, Onkologia</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak es</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszky Egyetemi Oktatokorhaz, Onkoradiologiai Osztaly</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Oncologia Medica Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.O. di Oncologia - Azienda USL di Rimini - Ospedale &quot;Cervesi&quot;</name>
      <address>
        <city>Cattolica</city>
        <zip>47841</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico O.C. Faenza</name>
      <address>
        <city>Faenza, RA</city>
        <zip>48018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Lugo</name>
      <address>
        <city>Lugo (RA)</city>
        <zip>48022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unita Sanitaria Locale di Rimini, U.O. di Oncologia ed Oncoematologia Ospedale degli Infermi</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Villa San Pietro</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center, Center for Breast Cancer</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pyatigorsk Oncology Center</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution &quot;Samara Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncotherapy, National Hospital</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastleigh Breast Care Centre</name>
      <address>
        <city>Pretoria</city>
        <zip>0041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico-Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico de Galicia</name>
      <address>
        <city>La Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology and Medical Radiology, SI &quot;DMA of MOH, Ukraine, &quot;MI &quot;Dnipropetrovsk City</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Treatment-and-Prophylactic Institution 'Donetsk City Oncological Dispensary' Radiology dep</name>
      <address>
        <city>Donetsk</city>
        <zip>83087</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal clinical treatment-and-propyilactic institution &quot;Donetsk regional oncology center',</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncologic Center</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv State Oncologic Regional Treatment and Diagnostic Centre</name>
      <address>
        <city>Lviv</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481003&amp;StudyName=Study%20Of%20Letrozole%20With%20Or%20Without%20Palbociclib%20%28PD-0332991%29%20For%20The%20First-Line%20Treatment%20Of%20Hormone-Receptor%20Positive%20Advanced%20Breast%20Ca</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2008</study_first_submitted>
  <study_first_submitted_qc>July 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2008</study_first_posted>
  <results_first_submitted>March 4, 2015</results_first_submitted>
  <results_first_submitted_qc>March 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 19, 2015</results_first_posted>
  <disposition_first_submitted>December 5, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>December 5, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 24, 2014</disposition_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hormone-receptor positive advanced breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This Phase 1/2, open-label, randomized study enrolled a total of 12 participants at 3 sites in the United States for Phase 1. Phase 1 participants received Palbociclib + Letrozole. In Phase 2, a total of 165 participants were randomized (84 in palbociclib plus letrozole arm and 81 in letrozole alone arm) at 50 sites in 12 countries.</recruitment_details>
      <pre_assignment_details>Phase 2 portion has 2 parts. Phase 2, Part 1 – ER positive, HER2 negative postmenopausal women with advanced breast cancer. Phase 2, Part 2- ER positive, HER2 negative postmenopausal women with tumors demonstrating CCND1 gene amplification and/or loss of CDKN2A gene.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1 (Palbociclib + Letrozole)</title>
          <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
        </group>
        <group group_id="P2">
          <title>Phase 2 (Palbociclib + Letrozole)</title>
          <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
        </group>
        <group group_id="P3">
          <title>Phase 2 (Letrozole)</title>
          <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing at date of cutoff</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Global deterioration of health status</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Objective progression or relapse</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 1 (Palbociclib + Letrozole)</title>
          <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
        </group>
        <group group_id="B2">
          <title>Phase 2 (Palbociclib + Letrozole)</title>
          <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
        </group>
        <group group_id="B3">
          <title>Phase 2 (Letrozole)</title>
          <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="177"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-44 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Maximum treatment duration (approximately 55 months)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of any agent of the combination.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 (Palbociclib + Letrozole)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of any agent of the combination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Grade 3 or 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Grade 5 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Related Adverse Events at Phase 1</title>
        <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Maximum treatment duration (approximately 55 months)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of any agent of the combination.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 (Palbociclib + Letrozole)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Related Adverse Events at Phase 1</title>
          <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of any agent of the combination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Grade 3 or 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Grade 5 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicities at Phase 1</title>
        <description>Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets &lt;25,000/μL, ANC &lt;500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count &lt;50,000/μL; ANC &lt;1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment.</description>
        <time_frame>Cycle 2 (4 weeks)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of any agent of the combination.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 (Palbociclib + Letrozole)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities at Phase 1</title>
          <description>Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets &lt;25,000/μL, ANC &lt;500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count &lt;50,000/μL; ANC &lt;1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of any agent of the combination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 4 Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;80% of doses due to elevated creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment</title>
        <description>PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs).</description>
        <time_frame>From randomization date to date of first documentation of progression or death (assessed up to 41 months)</time_frame>
        <population>Intent-to-Treat (ITT) was used. This represented all randomized participants from Ph2P1 or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment</title>
          <description>PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs).</description>
          <population>Intent-to-Treat (ITT) was used. This represented all randomized participants from Ph2P1 or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="13.8" upper_limit="27.5"/>
                    <measurement group_id="O2" value="10.2" lower_limit="5.7" upper_limit="12.6"/>
                    <measurement group_id="O3" value="26.1" lower_limit="11.2">Not reached</measurement>
                    <measurement group_id="O4" value="5.7" lower_limit="2.6" upper_limit="10.5"/>
                    <measurement group_id="O5" value="18.1" lower_limit="13.1" upper_limit="27.5"/>
                    <measurement group_id="O6" value="11.1" lower_limit="7.1" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis to be tested was H0: λ=1 versus. HA: λ&lt;1, where λ was the palbociclib plus letrozole:letrozole alone hazard ratio (HR). A HR less than 1 indicates a reduction in hazard rate in favor of Palbociclib + Letrozole. Stratified analysis was presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>1-sided p-value from the log-rank test stratified by stratification factors per randomization and Part.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.488</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.319</ci_lower_limit>
            <ci_upper_limit>0.748</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis to be tested was H0: λ=1 versus. HA: λ&lt;1, where λ was the palbociclib plus letrozole:letrozole alone hazard ratio (HR). A HR less than 1 indicates a reduction in hazard rate in favor of Palbociclib + Letrozole. Unstratified analysis was presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>1-sided p-value from the log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.299</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.572</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis to be tested was H0: λ=1 versus. HA: λ&lt;1, where λ was the palbociclib plus letrozole:letrozole alone hazard ratio (HR). A HR less than 1 indicates a reduction in hazard rate in favor of Palbociclib + Letrozole. Unstratified analysis was presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <p_value_desc>1-sided p-value from the log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.508</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.303</ci_lower_limit>
            <ci_upper_limit>0.853</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1</title>
        <description>Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.</description>
        <time_frame>From Baseline up to end of study (assessed up to 55 months)</time_frame>
        <population>Efficacy analysis set included all enrolled participants with the disease under study, adequate baseline disease assessment, and who started study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 (Palbociclib + Letrozole)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1</title>
          <description>Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.</description>
          <population>Efficacy analysis set included all enrolled participants with the disease under study, adequate baseline disease assessment, and who started study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="9.9" upper_limit="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1</title>
        <description>CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging &gt;= 4 weeks after initial response.</description>
        <time_frame>From Baseline up to end of study (assessed up to 55 months)</time_frame>
        <population>Efficacy analysis set included all enrolled participants with the disease under study, adequate baseline disease assessment, and who started study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 (Palbociclib + Letrozole)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1</title>
          <description>CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging &gt;= 4 weeks after initial response.</description>
          <population>Efficacy analysis set included all enrolled participants with the disease under study, adequate baseline disease assessment, and who started study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1</title>
        <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
        <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib Alone (Cycle 1 Day 14)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment.</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1</title>
          <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1982" spread="29"/>
                    <measurement group_id="O2" value="1933" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1</title>
        <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
        <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib Alone (Cycle 1 Day 14)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment.</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1</title>
          <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.8" spread="28"/>
                    <measurement group_id="O2" value="108.4" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1</title>
        <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
        <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib Alone (Cycle 1 Day 14)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment.</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1</title>
          <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" spread="28" lower_limit="2.17" upper_limit="8.20"/>
                    <measurement group_id="O2" value="7.92" spread="29" lower_limit="2.00" upper_limit="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1</title>
        <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
        <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib Alone (Cycle 1 Day 14)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment.</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1</title>
          <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.81" spread="5.0462" lower_limit="2.17" upper_limit="8.20"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.00" upper_limit="8.08">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1</title>
        <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
        <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib Alone (Cycle 1 Day 14)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment.</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1</title>
          <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.08" spread="29" lower_limit="2.17" upper_limit="8.20"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.00" upper_limit="8.08">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1</title>
        <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
        <time_frame>Cycle 1 Day 14, and Cycle 2 Day 14</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib Alone (Cycle 1 Day 14)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment.</description>
          </group>
          <group group_id="O2">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1</title>
          <description>On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2583" spread="26" lower_limit="2.17" upper_limit="8.20"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.00" upper_limit="8.08">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1</title>
        <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
        <time_frame>Cycle 2 Day 14, Cycle 2 Day 28</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>Participants received 125 mg oral doses of palbociclib with daily 2.5 mg doses of letrozole.</description>
          </group>
          <group group_id="O2">
            <title>Letrozole Alone (Cycle 2 Day 28)</title>
            <description>Participants received daily 2.5 mg doses of letrozole alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1</title>
          <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1739" spread="30" lower_limit="2.17" upper_limit="8.20"/>
                    <measurement group_id="O2" value="1936" spread="35" lower_limit="2.00" upper_limit="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1</title>
        <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
        <time_frame>Cycle 2 Day 14, and Cycle 2 Day 28</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>Participants received 125 mg oral doses of palbociclib with daily 2.5 mg doses of letrozole.</description>
          </group>
          <group group_id="O2">
            <title>Letrozole Alone (Cycle 2 Day 28)</title>
            <description>Participants received daily 2.5 mg doses of letrozole alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1</title>
          <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.95" spread="27" lower_limit="2.17" upper_limit="8.20"/>
                    <measurement group_id="O2" value="104.0" spread="31" lower_limit="2.00" upper_limit="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1</title>
        <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
        <time_frame>Cycle 2 Day 14, and Cycle 2 Day 28</time_frame>
        <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Palbociclib + Letrozole (Cycle 2 Day 14)</title>
            <description>Participants received 125 mg oral doses of palbociclib with daily 2.5 mg doses of letrozole.</description>
          </group>
          <group group_id="O2">
            <title>Letrozole Alone (Cycle 2 Day 28)</title>
            <description>Participants received daily 2.5 mg doses of letrozole alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1</title>
          <description>On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.</description>
          <population>The pharmacokinetic concentration set included all participants who were treated and had at least 1 concentration measurement in at least 1 pharmacokinetic assessment day. The pharmacokinetic parameter analysis set consisted of all participants treated who had at least 1 of the pharmacokinetic parameters of primary interest.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="27" lower_limit="0.833" upper_limit="4.13"/>
                    <measurement group_id="O2" value="1.04" spread="31" lower_limit="0.00" upper_limit="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1</title>
        <description>Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia’s formula (QTcF = QT divided by cube root of RR), by Bazette’s formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (&lt;) 60 msec(borderline) and greater than or equal to (&gt;=) 60 msec (prolonged) were summarized.</description>
        <time_frame>Cycle 1 Day 1 prior to dosing, Cycle 1 Day 14 (2, 4 [prior to meal], 8, 24, 48, and 96 hours after dosing of Palbociclib), Cycle 2 Day 1 and Day 14 (prior to and 4 hours after dosing of letrozole)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of any agent of the combination.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 (Palbociclib + Letrozole)</title>
            <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1</title>
          <description>Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia’s formula (QTcF = QT divided by cube root of RR), by Bazette’s formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (&lt;) 60 msec(borderline) and greater than or equal to (&gt;=) 60 msec (prolonged) were summarized.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of any agent of the combination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcB - Change &lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB - 30 ≤ change &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB - Change ≥60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF - Change &lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF - 30 ≤ change &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF - Change ≥60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcS - Change &lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcS - 30 ≤ change &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcS - Change ≥60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) at Phase 2</title>
        <description>Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months.</description>
        <time_frame>From randomization until death (assessed up to 41 months)</time_frame>
        <population>ITT was used. This represented all randomized participants from Ph2P1or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) at Phase 2</title>
          <description>Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months.</description>
          <population>ITT was used. This represented all randomized participants from Ph2P1or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="28.4">Not reached</measurement>
                    <measurement group_id="O2" value="33.3" lower_limit="26.4">Not reached</measurement>
                    <measurement group_id="O3" value="37.5" lower_limit="27.6">Not reached</measurement>
                    <measurement group_id="O4" value="33.3" lower_limit="26.0">Not reached</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="26.0">Not reached</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="23.4">Not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified analysis was presented above. Hazard ratio was assuming proportional hazards, a hazard ratio less than 1 indicated a reduction in hazard rate in favor of palbociclib + letrozole.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2105</p_value>
            <p_value_desc>1-sided p-value from the log-rank test stratified by Part (α = 0.10).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.813</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.492</ci_lower_limit>
            <ci_upper_limit>1.345</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3189</p_value>
            <p_value_desc>1-sided p-value from the unstratified log-rank test (α=0.10).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.844</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.417</ci_lower_limit>
            <ci_upper_limit>1.710</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2520</p_value>
            <p_value_desc>1-sided p-value from the unstratified log-rank test (α=0.10).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.783</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.382</ci_lower_limit>
            <ci_upper_limit>1.606</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment</title>
        <description>Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.</description>
        <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
        <population>ITT was used. This represented all randomized participants from Ph2P1or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment</title>
          <description>Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.</description>
          <population>ITT was used. This represented all randomized participants from Ph2P1or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="32.1" upper_limit="54.1"/>
                    <measurement group_id="O2" value="33.3" lower_limit="23.2" upper_limit="44.7"/>
                    <measurement group_id="O3" value="44.1" lower_limit="27.2" upper_limit="62.1"/>
                    <measurement group_id="O4" value="25.0" lower_limit="11.5" upper_limit="43.4"/>
                    <measurement group_id="O5" value="42.0" lower_limit="28.2" upper_limit="56.8"/>
                    <measurement group_id="O6" value="38.8" lower_limit="25.2" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Objective Response CI was calculated using the exact Clopper-Pearson method. The stratified analysis presented above was based on CMH test stratified by Part. An Odds Ratio &gt;1 means better response in favor of palbociclib + letrozole arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1347</p_value>
            <p_value_desc>1-sided p-value is from the stratified exact test (1-sided, α =0.10)</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above. Exact CI was based on Clopper-Pearson method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0849</p_value>
            <p_value_desc>Chi-square test was used (1-sided, α=0.10)</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>7.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above. Exact CI was based on Clopper-Pearson method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4515</p_value>
            <p_value_desc>Chi-square test was used (1-sided, α=0.10)</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment</title>
        <description>Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes).</description>
        <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
        <population>Participants in ITT population with measurable disease were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment</title>
          <description>Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes).</description>
          <population>Participants in ITT population with measurable disease were used.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" lower_limit="42.5" upper_limit="67.7"/>
                    <measurement group_id="O2" value="39.4" lower_limit="27.6" upper_limit="52.2"/>
                    <measurement group_id="O3" value="55.6" lower_limit="35.3" upper_limit="74.5"/>
                    <measurement group_id="O4" value="34.8" lower_limit="16.4" upper_limit="57.3"/>
                    <measurement group_id="O5" value="55.3" lower_limit="38.3" upper_limit="71.4"/>
                    <measurement group_id="O6" value="41.9" lower_limit="27.0" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Objective Response CI was calculated using the exact Clopper-Pearson method. The stratified analysis presented above was based on CMH test stratified by Part. An Odds Ratio &gt;1 means better response in favor of palbociclib + letrozole arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0471</p_value>
            <p_value_desc>1-sided p-value is from the stratified exact test (1-sided, α =0.10)</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>4.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above. Exact CI was based on Clopper-Pearson method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1180</p_value>
            <p_value_desc>Chi-square test was used (1-sided, α=0.10)</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>8.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above. Exact CI was based on Clopper-Pearson method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1631</p_value>
            <p_value_desc>Chi-square test was used (1-sided, α=0.10)</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>4.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response at Phase 2 - Investigator Assessment</title>
        <description>Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).</description>
        <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
        <population>A subset of ITT population i.e., participants who had response was used for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response at Phase 2 - Investigator Assessment</title>
          <description>Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).</description>
          <population>A subset of ITT population i.e., participants who had response was used for this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="13.4" upper_limit="25.8"/>
                    <measurement group_id="O2" value="11.1" lower_limit="9.3" upper_limit="31.6"/>
                    <measurement group_id="O3" value="20.9" lower_limit="6.2" upper_limit="25.8"/>
                    <measurement group_id="O4" value="10.8" lower_limit="3.7" upper_limit="31.6"/>
                    <measurement group_id="O5" value="20.2" lower_limit="13.0">Not reached</measurement>
                    <measurement group_id="O6" value="14.8" lower_limit="7.4">Not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CBR at Phase 2 - Investigator Assessment</title>
        <description>CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST.</description>
        <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
        <population>ITT was used. This represented all randomized patients from Ph2P1or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CBR at Phase 2 - Investigator Assessment</title>
          <description>CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST.</description>
          <population>ITT was used. This represented all randomized patients from Ph2P1or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="70.9" upper_limit="88.7"/>
                    <measurement group_id="O2" value="58.0" lower_limit="46.5" upper_limit="68.9"/>
                    <measurement group_id="O3" value="76.5" lower_limit="58.8" upper_limit="89.3"/>
                    <measurement group_id="O4" value="43.8" lower_limit="26.4" upper_limit="62.3"/>
                    <measurement group_id="O5" value="84.0" lower_limit="70.9" upper_limit="92.8"/>
                    <measurement group_id="O6" value="67.3" lower_limit="52.5" upper_limit="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CBR CI was calculated using the exact Clopper-Pearson method. The stratified analysis presented above was based on CMH test stratified by Part. An Odds Ratio &gt;1 means better response in favor of palbociclib + letrozole arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>1-sided p-value is from the stratified exact test (1-sided, α =0.10).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.48</ci_lower_limit>
            <ci_upper_limit>6.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above. Exact CI was based on Clopper-Pearson method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0065</p_value>
            <p_value_desc>Chi-square test was used (1-sided, α=0.10)</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>13.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above. Exact CI was based on Clopper-Pearson method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0442</p_value>
            <p_value_desc>Chi-square test was used (1-sided, α=0.10)</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>7.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment</title>
        <description>Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).</description>
        <time_frame>From randomization up to the end of treatment (approximately 41 months)</time_frame>
        <population>ITT was used. This represented all randomized participants from Ph2P1or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment</title>
          <description>Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).</description>
          <population>ITT was used. This represented all randomized participants from Ph2P1or Ph2P2 or Ph2P1+Ph2P2, where participants were classified according to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="13.8" upper_limit="27.5"/>
                    <measurement group_id="O2" value="10.2" lower_limit="5.7" upper_limit="12.6"/>
                    <measurement group_id="O3" value="26.1" lower_limit="11.2">Not reached</measurement>
                    <measurement group_id="O4" value="5.7" lower_limit="2.6" upper_limit="10.5"/>
                    <measurement group_id="O5" value="18.8" lower_limit="13.1" upper_limit="27.5"/>
                    <measurement group_id="O6" value="11.1" lower_limit="7.1" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier method was applied for median and 95% CI. Hazard ratio was based on assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of palbociclib + letrozole.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>1-sided p-value is from the stratified log-rank test (α =0.10).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.399</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.265</ci_lower_limit>
            <ci_upper_limit>0.601</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above. Kaplan-Meier method was applied for median and 95% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>1-sided p-value is from unstratified log-rank test (α=0.10).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.299</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.572</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis was presented above. Kaplan-Meier method was applied for median and 95% CI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <p_value_desc>1-sided p-value is from unstratified log-rank test (α=0.10).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.486</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.288</ci_lower_limit>
            <ci_upper_limit>0.822</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2</title>
        <description>The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (“no pain” or “does not interfere”) to 10 (“pain as bad as you can imagine” or “completely interferes”).</description>
        <time_frame>Baseline, End of treatment (approximately 41 months)</time_frame>
        <population>Patient reported outcome evaluable participants included participants who had received at least 1 dose of study medication, had baseline data, and at least one post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2</title>
          <description>The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (“no pain” or “does not interfere”) to 10 (“pain as bad as you can imagine” or “completely interferes”).</description>
          <population>Patient reported outcome evaluable participants included participants who had received at least 1 dose of study medication, had baseline data, and at least one post-baseline measurement.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at its worst in the last 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.42" lower_limit="28.4"/>
                    <measurement group_id="O2" value="0.1" spread="0.42" lower_limit="26.4"/>
                    <measurement group_id="O3" value="0.2" spread="0.60" lower_limit="27.6"/>
                    <measurement group_id="O4" value="0.0" spread="0.89" lower_limit="26.0"/>
                    <measurement group_id="O5" value="1.2" spread="0.55" lower_limit="26.0"/>
                    <measurement group_id="O6" value="0.1" spread="0.43" lower_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at its least in the last 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.27"/>
                    <measurement group_id="O2" value="0.4" spread="0.27"/>
                    <measurement group_id="O3" value="0.3" spread="0.31"/>
                    <measurement group_id="O4" value="0.7" spread="0.50"/>
                    <measurement group_id="O5" value="0.5" spread="0.40"/>
                    <measurement group_id="O6" value="0.2" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain on the average</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.33"/>
                    <measurement group_id="O2" value="0.2" spread="0.34"/>
                    <measurement group_id="O3" value="-0.1" spread="0.48"/>
                    <measurement group_id="O4" value="0.2" spread="0.64"/>
                    <measurement group_id="O5" value="0.4" spread="0.45"/>
                    <measurement group_id="O6" value="0.3" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain right now</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.35"/>
                    <measurement group_id="O2" value="0.1" spread="0.36"/>
                    <measurement group_id="O3" value="0.1" spread="0.31"/>
                    <measurement group_id="O4" value="0.3" spread="0.66"/>
                    <measurement group_id="O5" value="0.3" spread="0.55"/>
                    <measurement group_id="O6" value="0.0" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Severity Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.29"/>
                    <measurement group_id="O2" value="0.2" spread="0.32"/>
                    <measurement group_id="O3" value="0.0" spread="0.36"/>
                    <measurement group_id="O4" value="0.3" spread="0.62"/>
                    <measurement group_id="O5" value="0.6" spread="0.41"/>
                    <measurement group_id="O6" value="0.1" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented above is for Pain Severity Scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6900</p_value>
            <p_value_desc>P-values are based on 2-sample t-test.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented above is for Pain Severity Scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7125</p_value>
            <p_value_desc>P-values are based on 2-sample t-test.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented above is for Pain Severity Scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4012</p_value>
            <p_value_desc>P-values are based on 2-sample t-test.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2</title>
        <description>The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (“no pain” or “does not interfere”) to 10 (“pain as bad as you can imagine” or “completely interferes”).</description>
        <time_frame>Baseline, End of treatment (approximately 41 months)</time_frame>
        <population>Patient reported outcome evaluable participants included participants who had received at least 1 dose of study medication, had baseline data, and at least one post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2</title>
          <description>The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (“no pain” or “does not interfere”) to 10 (“pain as bad as you can imagine” or “completely interferes”).</description>
          <population>Patient reported outcome evaluable participants included participants who had received at least 1 dose of study medication, had baseline data, and at least one post-baseline measurement.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.40" lower_limit="28.4"/>
                    <measurement group_id="O2" value="0.2" spread="0.31" lower_limit="26.4"/>
                    <measurement group_id="O3" value="1.0" spread="0.66" lower_limit="27.6"/>
                    <measurement group_id="O4" value="0.2" spread="0.58" lower_limit="26.0"/>
                    <measurement group_id="O5" value="1.2" spread="0.51" lower_limit="26.0"/>
                    <measurement group_id="O6" value="0.3" spread="0.37" lower_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.50"/>
                    <measurement group_id="O2" value="0.2" spread="0.36"/>
                    <measurement group_id="O3" value="0.6" spread="0.72"/>
                    <measurement group_id="O4" value="-0.2" spread="0.62"/>
                    <measurement group_id="O5" value="1.0" spread="0.69"/>
                    <measurement group_id="O6" value="0.4" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking ability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.46"/>
                    <measurement group_id="O2" value="0.1" spread="0.35"/>
                    <measurement group_id="O3" value="1.0" spread="0.55"/>
                    <measurement group_id="O4" value="0.3" spread="0.63"/>
                    <measurement group_id="O5" value="0.7" spread="0.67"/>
                    <measurement group_id="O6" value="0.0" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.48"/>
                    <measurement group_id="O2" value="0.3" spread="0.39"/>
                    <measurement group_id="O3" value="1.0" spread="0.53"/>
                    <measurement group_id="O4" value="0.2" spread="0.74"/>
                    <measurement group_id="O5" value="0.5" spread="0.71"/>
                    <measurement group_id="O6" value="0.4" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.32"/>
                    <measurement group_id="O2" value="0.8" spread="0.32"/>
                    <measurement group_id="O3" value="0.6" spread="0.34"/>
                    <measurement group_id="O4" value="0.6" spread="0.60"/>
                    <measurement group_id="O5" value="0.9" spread="0.47"/>
                    <measurement group_id="O6" value="0.8" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.43"/>
                    <measurement group_id="O2" value="0.3" spread="0.35"/>
                    <measurement group_id="O3" value="0.1" spread="0.53"/>
                    <measurement group_id="O4" value="0.5" spread="0.63"/>
                    <measurement group_id="O5" value="0.9" spread="0.61"/>
                    <measurement group_id="O6" value="0.1" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.46"/>
                    <measurement group_id="O2" value="0.6" spread="0.41"/>
                    <measurement group_id="O3" value="0.4" spread="0.34"/>
                    <measurement group_id="O4" value="0.2" spread="0.69"/>
                    <measurement group_id="O5" value="1.1" spread="0.71"/>
                    <measurement group_id="O6" value="0.8" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.34"/>
                    <measurement group_id="O2" value="0.4" spread="0.30"/>
                    <measurement group_id="O3" value="0.7" spread="0.42"/>
                    <measurement group_id="O4" value="0.3" spread="0.56"/>
                    <measurement group_id="O5" value="0.9" spread="0.48"/>
                    <measurement group_id="O6" value="0.4" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented above is for Pain Interference Scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3346</p_value>
            <p_value_desc>P-values are based on 2-sample t-test.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented above is for Pain Interference Scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5630</p_value>
            <p_value_desc>P-values are based on 2-sample t-test.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented above is for Pain Severity Scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4427</p_value>
            <p_value_desc>P-values are based on 2-sample t-test.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1</title>
        <description>Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples.</description>
        <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
        <population>Copy number analysis set included participants in the Safety Analysis Set who had at least 1 of the biomarker assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1</title>
          <description>Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples.</description>
          <population>Copy number analysis set included participants in the Safety Analysis Set who had at least 1 of the biomarker assessments.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CCND1&gt;=1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="0.66" lower_limit="27.6"/>
                    <measurement group_id="O2" value="9" spread="0.58" lower_limit="26.0"/>
                    <measurement group_id="O3" value="39" spread="0.51" lower_limit="26.0"/>
                    <measurement group_id="O4" value="44" spread="0.37" lower_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p16/INK4A&lt;0.8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.72"/>
                    <measurement group_id="O2" value="2" spread="0.62"/>
                    <measurement group_id="O3" value="19" spread="0.69"/>
                    <measurement group_id="O4" value="12" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCND1&gt;=1.5 and p16/INK4A&lt;0.8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.55"/>
                    <measurement group_id="O2" value="2" spread="0.63"/>
                    <measurement group_id="O3" value="8" spread="0.67"/>
                    <measurement group_id="O4" value="8" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67</title>
        <description>Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups.</description>
        <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
        <population>All participants in the Safety Analysis set who had a Ki67 protein biomarker assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67</title>
          <description>Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups.</description>
          <population>All participants in the Safety Analysis set who had a Ki67 protein biomarker assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="0.40" lower_limit="28.4"/>
                    <measurement group_id="O2" value="31" spread="0.31" lower_limit="26.4"/>
                    <measurement group_id="O3" value="7" spread="0.66" lower_limit="27.6"/>
                    <measurement group_id="O4" value="16" spread="0.58" lower_limit="26.0"/>
                    <measurement group_id="O5" value="19" spread="0.51" lower_limit="26.0"/>
                    <measurement group_id="O6" value="15" spread="0.37" lower_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="0.50"/>
                    <measurement group_id="O2" value="40" spread="0.36"/>
                    <measurement group_id="O3" value="17" spread="0.72"/>
                    <measurement group_id="O4" value="10" spread="0.62"/>
                    <measurement group_id="O5" value="31" spread="0.69"/>
                    <measurement group_id="O6" value="30" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1</title>
        <description>Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression &gt;0 and Negative: any expression=0.</description>
        <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
        <population>Protein biomarkers analysis set included all participants in the safety analysis set who had at least protein biomarker assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1</title>
          <description>Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression &gt;0 and Negative: any expression=0.</description>
          <population>Protein biomarkers analysis set included all participants in the safety analysis set who had at least protein biomarker assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CyclinD1 - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="0.40" lower_limit="28.4"/>
                    <measurement group_id="O2" value="32" spread="0.31" lower_limit="26.4"/>
                    <measurement group_id="O3" value="10" spread="0.66" lower_limit="27.6"/>
                    <measurement group_id="O4" value="16" spread="0.58" lower_limit="26.0"/>
                    <measurement group_id="O5" value="31" spread="0.51" lower_limit="26.0"/>
                    <measurement group_id="O6" value="16" spread="0.37" lower_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CyclinD1 - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.50"/>
                    <measurement group_id="O2" value="3" spread="0.36"/>
                    <measurement group_id="O3" value="2" spread="0.72"/>
                    <measurement group_id="O4" value="0" spread="0.62"/>
                    <measurement group_id="O5" value="1" spread="0.69"/>
                    <measurement group_id="O6" value="3" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2</title>
        <description>Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group.</description>
        <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
        <population>Copy number analysis set included participants in the Safety Analysis Set who had at least 1 of the biomarker assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2</title>
          <description>Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group.</description>
          <population>Copy number analysis set included participants in the Safety Analysis Set who had at least 1 of the biomarker assessments.</population>
          <units>Copy number</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CCND1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="1.875" lower_limit="28.4"/>
                    <measurement group_id="O2" value="2.73" spread="1.559" lower_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p16/INK4A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.224"/>
                    <measurement group_id="O2" value="0.87" spread="0.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2</title>
        <description>One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed.</description>
        <time_frame>Screening visit (≤ 28 Days prior to dosing)</time_frame>
        <population>Polymorphism analysis set included participants in the safety analysis set who had at least 1 polymorphism assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2</title>
          <description>One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed.</description>
          <population>Polymorphism analysis set included participants in the safety analysis set who had at least 1 polymorphism assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CYP19A1 - A/A Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="0.42" lower_limit="28.4"/>
                    <measurement group_id="O2" value="5.4" spread="0.42" lower_limit="26.4"/>
                    <measurement group_id="O3" value="10.0" spread="0.60" lower_limit="27.6"/>
                    <measurement group_id="O4" value="10.7" spread="0.89" lower_limit="26.0"/>
                    <measurement group_id="O5" value="6.5" spread="0.55" lower_limit="26.0"/>
                    <measurement group_id="O6" value="2.2" spread="0.43" lower_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP19A1 - C/A Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="0.27"/>
                    <measurement group_id="O2" value="36.5" spread="0.27"/>
                    <measurement group_id="O3" value="33.3" spread="0.31"/>
                    <measurement group_id="O4" value="42.9" spread="0.50"/>
                    <measurement group_id="O5" value="34.8" spread="0.40"/>
                    <measurement group_id="O6" value="32.6" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP19A1 - C/C Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="0.33"/>
                    <measurement group_id="O2" value="58.1" spread="0.34"/>
                    <measurement group_id="O3" value="56.7" spread="0.48"/>
                    <measurement group_id="O4" value="46.4" spread="0.64"/>
                    <measurement group_id="O5" value="58.7" spread="0.45"/>
                    <measurement group_id="O6" value="65.2" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCND1 - A/A Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="0.35"/>
                    <measurement group_id="O2" value="28.4" spread="0.36"/>
                    <measurement group_id="O3" value="33.3" spread="0.31"/>
                    <measurement group_id="O4" value="39.3" spread="0.66"/>
                    <measurement group_id="O5" value="21.7" spread="0.55"/>
                    <measurement group_id="O6" value="21.7" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCND1 - G/A Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="0.29"/>
                    <measurement group_id="O2" value="47.3" spread="0.32"/>
                    <measurement group_id="O3" value="43.3" spread="0.36"/>
                    <measurement group_id="O4" value="42.9" spread="0.62"/>
                    <measurement group_id="O5" value="50.0" spread="0.41"/>
                    <measurement group_id="O6" value="50.0" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCND1 - G/G Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="24.3"/>
                    <measurement group_id="O3" value="23.3"/>
                    <measurement group_id="O4" value="17.9"/>
                    <measurement group_id="O5" value="28.3"/>
                    <measurement group_id="O6" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs (All Causalities) at Phase 2</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent adverse events were those with initial onset or that worsen in severity after the first dose of study medication.</description>
        <time_frame>Maximum treatment duration (approximately 41 months)</time_frame>
        <population>As treated set included all treated participants classified by the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs (All Causalities) at Phase 2</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent adverse events were those with initial onset or that worsen in severity after the first dose of study medication.</description>
          <population>As treated set included all treated participants classified by the treatment actually received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="0.42" lower_limit="28.4"/>
                    <measurement group_id="O2" value="65" spread="0.42" lower_limit="26.4"/>
                    <measurement group_id="O3" value="33" spread="0.60" lower_limit="27.6"/>
                    <measurement group_id="O4" value="25" spread="0.89" lower_limit="26.0"/>
                    <measurement group_id="O5" value="50" spread="0.55" lower_limit="26.0"/>
                    <measurement group_id="O6" value="40" spread="0.43" lower_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="0.27"/>
                    <measurement group_id="O2" value="5" spread="0.27"/>
                    <measurement group_id="O3" value="8" spread="0.31"/>
                    <measurement group_id="O4" value="2" spread="0.50"/>
                    <measurement group_id="O5" value="10" spread="0.40"/>
                    <measurement group_id="O6" value="3" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Grade 3 or 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="0.33"/>
                    <measurement group_id="O2" value="16" spread="0.34"/>
                    <measurement group_id="O3" value="28" spread="0.48"/>
                    <measurement group_id="O4" value="4" spread="0.64"/>
                    <measurement group_id="O5" value="36" spread="0.45"/>
                    <measurement group_id="O6" value="12" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Grade 5 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.35"/>
                    <measurement group_id="O2" value="0" spread="0.36"/>
                    <measurement group_id="O3" value="0" spread="0.31"/>
                    <measurement group_id="O4" value="0" spread="0.66"/>
                    <measurement group_id="O5" value="1" spread="0.55"/>
                    <measurement group_id="O6" value="0" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Related Adverse Events at Phase 2</title>
        <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Maximum treatment duration (approximately 41 months)</time_frame>
        <population>As treated set included all treated participants classified by the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Palbociclib + Letrozole)</title>
            <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 (Letrozole)</title>
            <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
          </group>
          <group group_id="O3">
            <title>Ph2P1 (Palbociclib + Letrozole)</title>
            <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O4">
            <title>Ph2P1 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
          <group group_id="O5">
            <title>Ph2P2 (Palbociclib + Letrozole)</title>
            <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
          </group>
          <group group_id="O6">
            <title>Ph2P2 (Letrozole)</title>
            <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Related Adverse Events at Phase 2</title>
          <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>As treated set included all treated participants classified by the treatment actually received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="0.42" lower_limit="28.4"/>
                    <measurement group_id="O2" value="32" spread="0.42" lower_limit="26.4"/>
                    <measurement group_id="O3" value="32" spread="0.60" lower_limit="27.6"/>
                    <measurement group_id="O4" value="13" spread="0.89" lower_limit="26.0"/>
                    <measurement group_id="O5" value="46" spread="0.55" lower_limit="26.0"/>
                    <measurement group_id="O6" value="19" spread="0.43" lower_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.27"/>
                    <measurement group_id="O2" value="0" spread="0.27"/>
                    <measurement group_id="O3" value="0" spread="0.31"/>
                    <measurement group_id="O4" value="0" spread="0.50"/>
                    <measurement group_id="O5" value="1" spread="0.40"/>
                    <measurement group_id="O6" value="0" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Grade 3 or 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="0.33"/>
                    <measurement group_id="O2" value="2" spread="0.34"/>
                    <measurement group_id="O3" value="25" spread="0.48"/>
                    <measurement group_id="O4" value="0" spread="0.64"/>
                    <measurement group_id="O5" value="29" spread="0.45"/>
                    <measurement group_id="O6" value="2" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Grade 5 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.35"/>
                    <measurement group_id="O2" value="0" spread="0.36"/>
                    <measurement group_id="O3" value="0" spread="0.31"/>
                    <measurement group_id="O4" value="0" spread="0.66"/>
                    <measurement group_id="O5" value="0" spread="0.55"/>
                    <measurement group_id="O6" value="0" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days after the last dose of study treatment</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant , or one participant may have experienced both a serious and nonserious event during the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1 (Palbociclib + Letrozole)</title>
          <description>In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.5 mg/d in a continuous regimen plus Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment.</description>
        </group>
        <group group_id="E2">
          <title>Phase 2 (Palbociclib + Letrozole)</title>
          <description>All participants who were randomized to letrozole plus palbociclib in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. In Ph2P1 and Ph2P2, the participants received palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
        </group>
        <group group_id="E3">
          <title>Phase 2 (Letrozole)</title>
          <description>All participants who were randomized to receive letrozole alone in both Phase 2 part 1 (Ph2P1) and Phase 2 part 2 (Ph2P2) are combined and presented. This was considered as control arm. Letrozole 2.5 mg/d was administered orally in a continuous regimen.</description>
        </group>
        <group group_id="E4">
          <title>Ph2P1 (Palbociclib + Letrozole)</title>
          <description>All participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
        </group>
        <group group_id="E5">
          <title>Ph2P1 (Letrozole)</title>
          <description>Participants were randomized to receive letrozole alone. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
        </group>
        <group group_id="E6">
          <title>Ph2P2 (Palbociclib + Letrozole)</title>
          <description>Participants were randomized to receive letrozole plus palbociclib. Palbociclib 125 mg/d orally for 3 weeks followed by 1 week off treatment and letrozole 2.5 mg/d orally in a continuous regimen.</description>
        </group>
        <group group_id="E7">
          <title>Ph2P2 (Letrozole)</title>
          <description>Participants were randomized to receive letrozole. Letrozole 2.5 mg/d was administered orally in a continuous regimen. This was considered as control arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (v16.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fallopian tube cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (v16.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple allergies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Ingrown hair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

